Phosphorylated GSK3β-ser9 and EGFR are good prognostic factors for lung carcinomas

Anticancer Research

Volumn 27, Issue 5 B, 2007, Pages 3561-3569

  Zheng, Huachuan ^a,c   Saito, Hiroshi ^b   Masuda, Shinji ^b   Yang, Xianghong ^c   Takano, Yasuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Kouseiren Takaoka Hospital   (Japan)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial growth factor receptor; Lung carcinoma; P GSK3 ser9; Prognosis; Progression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; KI 67 ANTIGEN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SERINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PHOSPHOSERINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 10; CONTROLLED STUDY; FEMALE; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEQUENCE HOMOLOGY; TISSUE MICROARRAY; ENZYMOLOGY; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLATION; PHOSPHOSERINE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 35348953179     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Droucheau E, Primot A, Thomas V, Mattei D, Knockaert M, Richardson C, Sallicandro P, Alano P, Jafarshad A, Baratte B, Kunick C, Parzy D, Pearl L, Doerig C and Meijer L: Plasmodium falciparum glycogen synthase kinase-3: molecular model, expression, intracellular localisation and selective inhibitors. Biochim Biophys Acta 1697: 181-196, 2004.
2. Ali A, Hoeflich KP and Woodgett JR: Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev 101: 2527-2540, 2001.
3. Frame S and Cohen P: GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359: 1-16, 2001.
4. Acevedo N, Wang X, Dunn RL and Smith GD: Glycogen synthase kinase-3 regulation of chromatin segregation and cytokinesis in mouse preimplantation embryos. Mol Reprod Dev 74: 178-188, 2007.
5. Mulholland DJ, Dedhar S, Wu H and Nelson CC: PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 5: 329-337, 2006.
6. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y and Minamoto T: Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334: 1365-1373, 2005.
7. Patel S, Doble B and Woodgett JR: Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword? Biochem Soc Trans 32: 803-808, 2004.
8. Kim L and Kimmel AR: GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev 10: 508-514, 2000.
9. Pearl LH and Barford D: Regulation of protein kinases in insulin, growth factor and Wnt signalling. Curr Opin Struct Biol 12: 761-767, 2002.
10. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A and Paradiso A: The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 1766: 120-139, 2006.
11. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M and Griffin JD: Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65: 8968-8974, 2005.
12. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR and Meyerson M: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2: e313, 2005.
13. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
14. Normanno N, Bianco C, De Luca A, Maiello MR and Salomon DS: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10: 1-21, 2003.
15. Grimes CA and Jope RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65: 391-426, 2001.
16. Wang J, Cheng YW, Wu DW, Chen JT, Chen CY, Chou MC and Lee H: Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan. Cancer Lett 235: 18-25, 2006.
17. Akyurek N, Memis L, Ekinci O, Kokturk N and Ozturk C: Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Arch 449: 164-170, 2006.
18. Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: World Health Organization Classification of Tumors: Pathology & Genetics, Tumors of the Lung, Pleura, Thymus and Heart. IARCPress and Oxford University Press, 2000.
19. Sobin LH and Wittekind CH: TNM Classification of Malignant Tumors. 6th edition. John Wiley & Sons, Hoboken, New Jersey, 2002.
20. Kumada T, Tsuneyama K, Hatta H, Ishizawa S and Takano Y: Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol 17: 1141-1149, 2004.
21. Ban KC, Singh H, Krishnan R and Seow HF: GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma. Cancer Lett 199: 201-208, 2003.
22. Desbois-Mouthon C, Blivet-Van Eggelpoel MJ, Beurel E, Boissan M, Delelo R, Cadoret A and Capeau J: Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells. Hepatology 36: 1528-1536, 2002.
23. Sonobe M, Nakagawa M, Takenaka K, Katakura H, Adachi M, Yanagihara K, Otake Y, Wada H and Tanaka F: Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. J Surg Oncol 95: 63-69, 2006.
24. Tokumo M, Toyooka S, Ichihara S, Ohashi K, Tsukuda K, Ichimura K, Tabata M, Kiura K, Aoe M, Sano Y, Date H and Shimizu N: Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer 53: 117-121, 2006.
25. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T and Tamura T: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829-6837, 2005.
26. Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C and Yousem SA: Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol 125: 860-865, 2006.
27. Sithanandam G, Smith GT, Masuda A, Takahashi T, Anderson LM and Fornwald LW: Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway. Carcinogenesis 24: 1581-1592, 2003.
28. Ahn JH, Kim SW, Hong SM, Suh C, Kim WK, Lee IC and Lee JS: Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma. J Korean Med Sci 19: 529-535, 2004.
29. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi H, Angeletti CA, Pingitore R, Pepe S, Basolo F and Bevilacqua G: Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 31A: 178-183, 1995.
30. Xue C, Wyckoff J, Liang F, Sidani M, Violini S, Tsai KL, Zhang ZY, Sahai E, Condeelis J and Segall JE: Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 66: 192-197, 2006.
31. Mammano E, Belluco C, Sciro M, Mencarelli R, Agostini M, Michelotto M, Marchet A and Nitti D: Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer. Anticancer Res 26: 3547-3550, 2006.
32. Zheng H, Tsuneyama K, Cheng C, Takahashi H, Cui Z, Murai Y, Nomoto K and Takano Y: An immunohistochemical study of p53 and Ki-67 in gastrointestinal adenoma and adenocarcinoma using tissue microarray. Anticancer Res 26: 2353-2360, 2006.
33. Niemiec J, Kolodziejski L and Dyczek S: EGFR LI and Ki-67 LI are independent prognostic parameters influencing survivals of surgically treated squamous cell lung cancer patients. Neoplasma 52: 231-237, 2005.